| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.015 | 0.8 |